NASDAQ$PAYS

Paysign Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Reported financial results for the fourth-quarter and fiscal year 2020.

Paysign's Q4 2020 results were impacted by the COVID-19 pandemic, particularly affecting clients in the pharma and plasma industries. The company added 55 new plasma programs and experienced a net growth in card programs of 61. Paysign remains well-capitalized with $7.8 million of unrestricted cash and zero debt.

  • COVID-19 pandemic negatively impacted clients in the pharma and plasma industries.
  • The month of May marked the low point for the plasma business, with improvements seen throughout the year.
  • 55 new plasma programs were added, and there was a net growth in card programs of 61.
  • The company remains well-capitalized with $7.8 million of unrestricted cash and zero debt.

Headline financials

Total Revenue

$7.25M

Previous: $9.77M-25.7%
EPS (adj)

$0.01

Previous: $0.05-80.0%
Capital Expenditures

$287K

Previous: $112K+155.2%
Free Cash Flow

$910K

Previous: $5.8M-84.3%
Net Income

-$4.31M

Previous: $7.45M-157.8%
Operating Income

-$658K

Previous: $1.45M-145.3%
Gross Profit

$3.71M

Previous: $5.06M-26.7%
Cash & Equivalents

$7.83M

Previous: $45.6M-82.8%
Total Assets

$67.8M

Previous: $53.5M+26.7%
Stock-Based Comp

$848K

Previous: $663K+28.0%

Revenue & EPS history

Paysign · Revenue · Quarterly

$7.25M

Q4 2020-25.7%vs Q4 2019
Beat estimate in 5 of 12 quarters(42%)
ActualEstimate

Forward guidance

Paysign anticipates that COVID-19 and government stimulus measures will likely continue to impact its business into 2021. The company remains cautiously optimistic that its businesses will continue to rebound as vaccinations become more prevalent and business restrictions are lifted.

Tailwinds

  • Optimistic outlook in the recovery of the pharma and plasma industries.
  • Company's ability to return to year-over-year growth.
  • Company remains well-capitalized and positioned to weather impacts from the pandemic.
  • Expects an upturn in the second half of 2021 resulting from vaccinations becoming more prevalent
  • Expects an upturn in the second half of 2021 resulting from business restrictions being lifted.

Headwinds

  • The pandemic continues to have a meaningful impact on the company’s business and operations
  • Inability to continue current growth rate in future periods.
  • Downturn in the economy, including as a result of COVID-19, as well as government stimulus measures, could reduce customer base and demand for products and services.
  • Operating in a highly regulated environment
  • Failure by us or business partners to comply with applicable laws and regulations

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

+16.2%

Avg return

Earnings day

+4.1%

Avg return

5 days after

+7.8%

Avg return

30 days after

44%

27 / 61 earnings

Positive

+900.0%

Q3 2011

Best reaction

-29.6%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+37.3%-4.3%
Q1 2026-12.6%-12.0%+4.8%
Q3 2025+0.2%-8.8%+0.4%
Q2 2025+13.0%+4.2%+0.6%
Q1 2025+3.0%+22.9%+81.9%
Q4 2024-8.5%-14.5%-8.1%
Q3 2024+10.9%+8.7%-7.9%
Q2 2024-6.7%-14.4%-9.2%
Q1 2024-0.4%+5.4%-7.6%
Q4 2023+20.5%+10.2%+31.9%
Q3 2023+18.1%+21.6%+18.1%
Q2 2023+6.4%+8.6%+16.0%
Q1 2023-1.8%-4.5%-20.7%
Q4 2022+4.2%+7.6%+0.3%
Q3 2022-10.4%+8.9%+16.5%
Q2 2022+7.4%+15.3%+33.5%
Q1 2022-26.2%-20.2%-2.4%
Q4 2021-6.6%-16.6%-21.4%
Q3 2021-9.0%-14.6%-32.8%
Q2 2021-2.4%+5.6%+16.7%
Q1 2021-11.4%-10.8%+0.0%
Q4 2020+11.7%+5.1%+0.8%
Q3 2020-26.8%-20.6%-7.7%
Q2 2020-18.9%-30.5%-45.3%
Q1 2020-5.5%-13.0%-0.4%
Q4 2019+27.3%+82.9%+102.7%
Q3 2019+13.2%+17.1%+3.9%
Q2 2019+2.5%+6.3%+2.7%
Q1 2019-11.7%-6.7%+18.2%
Q4 2018-1.7%-7.5%-1.0%
Q3 2018-0.5%-1.6%-6.3%
Q2 2018+10.1%+2.7%-2.7%
Q1 2018-0.9%+18.8%+23.1%
Q4 2017+19.0%+20.6%+44.3%
Q3 2017+7.9%+19.3%+15.8%
Q2 2017+2.8%+9.4%+0.0%
Q1 2017-8.7%-6.5%-6.5%
Q4 2016+4.7%+0.0%+0.0%
Q3 2016+34.9%+73.7%+73.7%
Q2 2016+0.0%-5.0%-20.0%
Q1 2016-23.2%
Q4 2015-29.6%
Q3 2015-12.0%
Q2 2015+6.3%
Q1 2015+4.3%
Q4 2014+71.2%
Q2 2014-16.7%
Q1 2014+0.0%
Q4 2013+23.4%
Q3 2013-17.9%
Q2 2013-16.6%
Q4 2012-4.3%
Q1 2013-4.3%
Q3 2012+18.5%
Q2 2012+0.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+900.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010+5.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro